BeOne Medicines Ltd. - ADR earnings per share and revenue
On Nov 06, 2025, ONC reported earnings of 0.57 USD per share (EPS) for Q3 25, missing the estimate of 0.60 USD, resulting in a -5.45% surprise. Revenue reached 10.11 billion, compared to an expected 10.25 billion, with a -1.37% difference. The market reacted with a -3.73% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 analysts forecast an EPS of 0.62 USD, with revenue projected to reach 10.96 billion USD, implying an increase of 8.77% EPS, and increase of 8.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were BeOne Medicines Ltd. - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, BeOne Medicines Ltd. - ADR reported EPS of $0.57, missing estimates by -5.45%, and revenue of $10.11B, -1.37% below expectations.
How did the market react to BeOne Medicines Ltd. - ADR's Q3 2025 earnings?
The stock price moved down -3.73%, changed from $332.36 before the earnings release to $319.97 the day after.
When is BeOne Medicines Ltd. - ADR expected to report next?
The next earning report is scheduled for Apr 15, 2026.
What are the forecasts for BeOne Medicines Ltd. - ADR's next earnings report?
Based on 2
analysts, BeOne Medicines Ltd. - ADR is expected to report EPS of $0.62 and revenue of $10.96B for Q4 2025.